Drug Delivery Platforms
•230 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (230)
| Company | Market Cap | Price |
|---|---|---|
|
LRMR
Larimar Therapeutics, Inc.
The CPP-based delivery platform is a core technology used to deliver nomlabofusp, i.e., Drug Delivery Platforms.
|
$304.70M |
$3.65
+2.39%
|
|
SCPH
scPharmaceuticals Inc.
Drug Delivery Platforms is a core technology enabling the subcutaneous administration of FUROSCIX.
|
$299.33M |
$5.67
|
|
PYXS
Pyxis Oncology, Inc.
MICVO employs a drug-delivery platform approach (extracellular matrix targeting with a cleavable linker and cytotoxic payload).
|
$297.69M |
$5.14
+7.08%
|
|
SLN
Silence Therapeutics plc
Platform-based drug delivery (GalNAc-siRNA) enabling targeted delivery for siRNA therapies.
|
$297.63M |
$6.20
-1.74%
|
|
ALDX
Aldeyra Therapeutics, Inc.
RASP modulation platform described as a drug-delivery/platform technology.
|
$297.08M |
$5.21
+4.94%
|
|
NGNE
Neurogene Inc.
EXACT is a proprietary platform technology for drug delivery/regulation of transgene expression in gene therapy.
|
$286.29M |
$20.46
+1.99%
|
|
TARA
Protara Therapeutics, Inc.
IV Choline Chloride is described as a platform for phospholipid substrate replacement, i.e., a Drug Delivery Platform.
|
$280.10M |
$7.47
+2.96%
|
|
DBVT
DBV Technologies S.A.
Viaskin Peanut EPIT patch is a drug-delivery platform; DBV Technologies directly develops and commercializes this patch-based immunotherapy.
|
$265.38M |
$13.14
-4.40%
|
|
CAPR
Capricor Therapeutics, Inc.
StealthX is described as an exosome-based drug delivery platform for targeted cargo delivery.
|
$262.87M |
$4.57
-20.52%
|
|
TLSI
TriSalus Life Sciences, Inc.
Core PEDD drug-delivery platform technology powering TriNav systems.
|
$252.83M |
$5.86
+15.48%
|
|
CADL
Candel Therapeutics, Inc.
enLIGHTEN HSV-based platform represents a drug delivery platform used to design and optimize viral immunotherapies.
|
$249.77M |
$4.55
|
|
OBIO
Orchestra BioMed Holdings, Inc.
Virtue SAB represents a drug-delivery platform delivering extended-release sirolimus to the vessel wall.
|
$244.42M |
$4.84
+6.84%
|
|
CPMV
Mosaic ImmunoEngineering Inc.
Drug delivery platforms tag fits the proprietary plant virus nanoparticle delivery technology used to modulate immune responses.
|
$240.84M |
$0.60
|
|
VYGR
Voyager Therapeutics, Inc.
ALPL-based non-viral shuttle and TRACER capsids represent a Drug Delivery Platforms technology.
|
$231.86M |
$4.07
-2.75%
|
|
EPRX
Eupraxia Pharmaceuticals Inc.
Diffusphere is Eupraxia's proprietary drug-delivery platform enabling localized, extended-release formulation, a core product/technology they directly develop and apply to its pipeline candidates EP-104IAR and EP-104GI.
|
$221.22M |
$6.25
+0.72%
|
|
EDIT
Editas Medicine, Inc.
Drug Delivery Platforms: proprietary delivery platform (tLNP) enabling in vivo gene editing.
|
$217.61M |
$2.48
+2.69%
|
|
MIST
Milestone Pharmaceuticals Inc.
Milestone's nasal spray represents a drug delivery platform/format for self-administration.
|
$203.99M |
$2.37
-1.25%
|
|
GNLX
Genelux Corporation
CHOICE is a platform-based drug delivery approach for immunotherapies, fitting Drug Delivery Platforms.
|
$187.36M |
$5.06
+2.02%
|
|
PEPG
PepGen Inc.
The Enhanced Delivery Oligonucleotide (EDO) platform represents a drug delivery technology, justifying the Drug Delivery Platforms tag.
|
$182.37M |
$5.78
+3.87%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA utilizes an intranasal delivery method for Foralumab, representing a Drug Delivery Platforms approach.
|
$179.37M |
$1.73
-0.86%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Core technology platforms STARR sa-mRNA and LUNAR delivery system enabling RNA therapeutics.
|
$169.99M |
$6.11
-2.40%
|
|
HRTX
Heron Therapeutics, Inc.
Biochronomer drug-delivery technology is a platform enabling extended-release formulations across Heron's products.
|
$162.49M |
$1.08
+2.36%
|
|
THTX
Theratechnologies Inc.
SORT1+ Technology platform functions as a drug-delivery platform enabling peptide-drug conjugates.
|
$155.87M |
$3.39
|
|
CATX
Perspective Therapeutics, Inc.
Developing a drug-delivery platform around the 212Pb radiopharmaceuticals and regional finishing capabilities.
|
$155.21M |
$2.18
+4.31%
|
|
MCRB
Seres Therapeutics, Inc.
MbTx Platform is Seres' core drug-delivery platform enabling the design and cultivation of targeted live biotherapeutic consortia.
|
$155.04M |
$16.81
-5.08%
|
|
RLMD
Relmada Therapeutics, Inc.
NDV-01 employs a sustained-release drug-delivery platform for intravesical administration.
|
$141.73M |
$4.24
-0.82%
|
|
VTGN
VistaGen Therapeutics, Inc.
Pherine platform represents a non-systemic intranasal drug-delivery approach developed by the company.
|
$140.82M |
$4.77
+3.92%
|
|
ELTX
Elicio Therapeutics, Inc.
AMP platform described as a drug delivery platform targeting lymph nodes.
|
$138.06M |
$8.56
+1.36%
|
|
MRSN
Mersana Therapeutics, Inc.
Dolasynthen and Immunosynthen platforms are drug delivery platforms enabling targeted ADC payload delivery.
|
$136.25M |
$27.74
+1.61%
|
|
MOLN
Molecular Partners AG
DARPin platform represents a drug-delivery/modular platform enabling targeted biologics.
|
$134.10M |
$4.19
+3.71%
|
|
SGMO
Sangamo Therapeutics, Inc.
STAC-BBB represents a CNS drug-delivery platform enabling systemic delivery across the blood-brain barrier.
|
$127.74M |
$0.41
-2.20%
|
|
ALEC
Alector, Inc.
Alector Brain Carrier (ABC) is a proprietary drug delivery platform to enhance brain exposure and enable subcutaneous administration.
|
$125.50M |
$1.28
+3.23%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RaniPill is the core drug-delivery platform enabling oral administration of biologics, central to the company's offering.
|
$117.15M |
$1.69
+3.37%
|
|
ENTX
Entera Bio Ltd.
Entera Bio's N-Tab platform is a drug-delivery platform enabling oral administration of large-molecule peptides.
|
$115.53M |
$2.54
+0.40%
|
|
QNCX
Quince Therapeutics, Inc.
Quince's AIDE platform is a drug-delivery platform encapsulating drugs in autologous red blood cells.
|
$114.95M |
$2.54
+18.69%
|
|
NTHI
NEONC TECHNOLOGIES HOLDINGS, INC.
Proprietary drug delivery platform enabling brain tumor targeting and BBB bypass; platform used for delivery of therapeutics.
|
$112.27M |
$7.05
+20.31%
|
|
CYBN
Cybin Inc.
CYB004 utilizes a deuterated drug delivery approach including an inhalation platform, indicating a Drug Delivery Platforms capability.
|
$111.81M |
$5.91
+5.72%
|
|
IKT
Inhibikase Therapeutics, Inc.
Prodrug technology used in IKT-001Pro represents a drug-delivery platform approach.
|
$111.03M |
$1.53
+2.68%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oramed's POD platform constitutes the core drug-delivery technology enabling oral administration of therapeutic proteins (e.g., oral insulin).
|
$105.79M |
$2.56
-0.78%
|
|
SLGL
Sol-Gel Technologies Ltd.
Proprietary microencapsulation drug-delivery platform is a core technology Sol-Gel uses to formulate topical therapies.
|
$102.10M |
$37.98
+3.63%
|
|
INO
Inovio Pharmaceuticals, Inc.
CELLECTRA delivery technology represents a drug delivery platform enabling in vivo DNA plasmid delivery.
|
$93.53M |
$1.78
+1.42%
|
|
ACOG
Alpha Cognition Inc. Common Stock
The company references sublingual and coated tablet formulations, indicating a drug delivery platform focus.
|
$92.92M |
$5.83
+1.39%
|
|
CLNN
Clene Inc.
Clene's proprietary clean-surfaced nanotechnology platform operates as a drug delivery platform for CNM-Au8.
|
$92.61M |
$9.16
-1.19%
|
|
TVGN
Tevogen Bio Holdings Inc.
ExacTcell and TVGN platform described as a drug delivery platform enabling cell therapies.
|
$88.69M |
$0.44
-3.08%
|
|
ADVM
Adverum Biotechnologies, Inc.
The program relies on a proprietary drug delivery platform (vector-based) for sustained expression of a therapeutic protein.
|
$86.87M |
$4.11
-0.85%
|
|
VXRT
Vaxart, Inc.
The VAAST platform constitutes a Drug Delivery Platform enabling oral, needle-free vaccines with mucosal immunity and room-temperature stability.
|
$83.11M |
$0.36
|
|
ADAG
Adagene Inc.
Drug Delivery Platforms capturing the platform-based approach to activating antibodies in tumors.
|
$79.69M |
$1.89
+5.00%
|
|
VANI
Vivani Medical, Inc.
Vivani's NanoPortal is a proprietary drug-implant platform enabling ultra long-acting, localized drug delivery.
|
$78.20M |
$1.30
-1.14%
|
|
ALXO
ALX Oncology Holdings Inc.
ALX2004 leverages a proprietary linker-payload platform, aligning with the Drug Delivery Platforms category.
|
$76.58M |
$1.50
+5.24%
|
|
ARTV
Artiva Biotherapeutics, Inc.
AlloNK represents a drug-delivery platform concept (off-the-shelf cell therapy) enabling administration of therapy.
|
$76.45M |
$3.26
+4.15%
|
|
STRO
Sutro Biopharma, Inc.
XpressCF+/ADC platform constitutes a drug delivery platform used to create and optimize ADCs.
|
$71.49M |
$0.87
+3.04%
|
|
ASRT
Assertio Holdings, Inc.
Sympazan's PharmFilm technology and related drug-delivery approaches indicate a Drug Delivery Platforms capability.
|
$69.22M |
$0.71
-1.57%
|
|
BMEA
Biomea Fusion, Inc.
Platform technology (FUSION System) used to discover/develop covalent small molecule drugs, representing a drug discovery platform.
|
$58.44M |
$0.99
+1.14%
|
|
OSTX
OS Therapies Incorporated
Drug Delivery Platforms tag captures the tunable linker/ delivery platform used in OST-tADC.
|
$54.54M |
$1.71
-0.29%
|
|
NTRB
Nutriband Inc.
Direct AVERSA drug-delivery platform enabling abuse-deterrent transdermal patches (lead product AVERSA Fentanyl) and related patch technologies.
|
$53.32M |
$4.67
-2.20%
|
|
BCAB
BioAtla, Inc.
CAB platform is a conditional antibody/drug delivery platform used to activate drug in tumor microenvironment.
|
$51.04M |
$0.77
-11.06%
|
|
SIGY
Sigyn Therapeutics, Inc.
ChemoPrep/ChemoPure platforms imply drug-delivery optimization via extracorporeal circuits, fitting Drug Delivery Platforms.
|
$47.86M |
$1.40
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Directly markets/provides a proprietary drug-delivery platform (D-MNA) enabling localized chemotherapy delivery.
|
$46.57M |
$2.06
-3.29%
|
|
CUE
Cue Biopharma, Inc.
Immuno-STAT represents a drug delivery platform for targeted, injectable biologics.
|
$45.72M |
$0.57
-4.03%
|
|
GRCE
Grace Therapeutics, Inc.
The company emphasizes proprietary drug-delivery platforms to reformulate existing compounds, a clear fit for 'Drug Delivery Platforms'.
|
$44.11M |
$3.13
-1.72%
|
|
ATNM
Actinium Pharmaceuticals, Inc.
ARC/Radiopharmaceutical platform represents a drug delivery platform enabling targeted radiotherapy.
|
$41.49M |
$1.38
+3.76%
|
|
JUNS
Jupiter Neurosciences, Inc.
Drug Delivery Platforms: JOTROL is a proprietary micellar delivery system improving bioavailability.
|
$41.10M |
$1.19
+0.42%
|
|
SER
Serina Therapeutics, Inc.
Direct proprietary POZ drug delivery platform enabling long-acting, subcutaneous drug release for CNS therapeutics.
|
$40.90M |
$3.81
-4.51%
|
|
HOWL
Werewolf Therapeutics, Inc.
PREDATOR platform represents a drug delivery platform enabling tumor-selective activation.
|
$39.93M |
$0.97
+11.41%
|
|
VRCA
Verrica Pharmaceuticals Inc.
YCANTH uses a proprietary drug-device combination applicator, aligning with a drug delivery platform.
|
$39.77M |
$4.83
+14.73%
|
|
XLO
Xilio Therapeutics, Inc.
Drug Delivery Platforms reflects Xilio's tumor-activation masking technology designed to localize activity within tumors.
|
$39.03M |
$0.76
+0.92%
|
|
ATHE
Alterity Therapeutics Limited
Alterity's iron chaperone platform represents a drug-delivery/platform technology that redistributes iron to modulate disease pathways.
|
$37.35M |
$3.79
+7.83%
|
|
APLT
Applied Therapeutics, Inc.
ARI platform represents a drug-delivery/targeting platform aiming for tissue-specific penetration, a defined drug-delivery platform category.
|
$37.26M |
$0.24
-6.61%
|
|
OTLC
Oncotelic Therapeutics, Inc.
Nanoparticle-based delivery platform for six anticancer agents constitutes a Drug Delivery Platform.
|
$37.21M |
$0.09
|
|
MURA
Mural Oncology plc
Engineered cytokine platform underlying the programs represents a Drug Delivery Platform/therapeutic delivery approach.
|
$36.21M |
$2.10
+0.24%
|
|
RNTX
Rein Therapeutics Inc.
LTI-3.00 employs a dry powder inhalation delivery approach, representing a Drug Delivery Platforms category.
|
$34.49M |
$1.50
+1.35%
|
|
GBIO
Generation Bio Co.
ctLNP is a proprietary drug delivery platform enabling targeted, redosable delivery of nucleic acids.
|
$33.77M |
$5.14
+2.51%
|
|
NMTC
NeuroOne Medical Technologies Corporation
sEEG-based drug delivery system platform enabling localized therapeutic delivery from neural implants.
|
$31.68M |
$0.65
+2.15%
|
|
GNTA
Genenta Science S.p.A.
Temferon uses a drug-delivery platform to express payloads in the tumor microenvironment.
|
$30.73M |
$1.77
+5.65%
|
|
NXTC
NextCure, Inc.
NextCure’s ADC technology represents a drug delivery platform that enables targeted payload delivery to tumors.
|
$28.13M |
$13.19
+25.45%
|
|
BTAI
BioXcel Therapeutics, Inc.
Sublingual film formulation BXCL501 represents a drug-delivery platform; included as Drug Delivery Platforms.
|
$27.80M |
$1.93
+0.79%
|
|
TLPH
Talphera, Inc.
The company emphasizes drug delivery platform concepts through lyophilized nafamostat formulations and IV/compounded administration approaches.
|
$27.50M |
$1.40
+4.48%
|
|
ELUT
Elutia Inc.
EluPro embodies a Drug Delivery Platform delivering antibiotics from the biomatrix at the implant site.
|
$25.02M |
$0.60
+1.37%
|
|
PASG
Passage Bio, Inc.
PBFT02 leverages a drug delivery platform (AAV1/ICM) to deliver progranulin to the CNS.
|
$24.59M |
$8.20
+6.01%
|
|
DARE
Daré Bioscience, Inc.
Drug Delivery Platforms: Daré's core IDDS platform is used to deliver hormones and contraceptive agents (e.g., DARE-LARC1) and supports multiple pipeline programs, making this a primary product/technology category.
|
$22.65M |
$1.80
+7.14%
|
|
AKTX
Akari Therapeutics, Plc
Drug delivery platforms conceptually underpin the novel ADC payloads and linker technologies.
|
$22.28M |
$0.44
-1.40%
|
|
IBIO
iBio, Inc.
ShieldTx and related antibody engineering imply a Drug Delivery Platform approach to spatially control activity.
|
$20.64M |
$1.08
+3.33%
|
|
COSM
Cosmos Health Inc.
Uses nanoemulsification technology to enhance absorption (e.g., Melatonin Spray), representing a Drug Delivery Platforms capability.
|
$20.47M |
$0.71
+4.25%
|
|
AYTU
Aytu BioPharma, Inc.
The company employs a Time Release Resin Particle (TRRP) proprietary technology, aligning with the 'Drug Delivery Platforms' category.
|
$19.92M |
$2.08
+3.73%
|
|
PALI
Palisade Bio, Inc.
PALI-2108 employs a gut-restricted prodrug delivery approach, representing a Drug Delivery Platforms technology.
|
$19.42M |
$2.26
+6.10%
|
|
INTS
Intensity Therapeutics, Inc.
DfuseRx platform and INT230-6.00 involve a drug-delivery platform enabling intratumoral delivery and systemic immune effects.
|
$19.21M |
$0.43
+4.43%
|
|
SYBX
Synlogic, Inc.
Synlogic positions its Synthetic Biotics as a Drug Delivery Platform enabling localized GI therapy.
|
$18.84M |
$1.62
+0.62%
|
|
LEXX
Lexaria Bioscience Corp.
Lexaria's DehydraTECH is a proprietary drug delivery platform that enhances API absorption and enables oral formulations.
|
$18.44M |
$1.04
-0.95%
|
|
PYPD
PolyPid Ltd.
D-PLEX100 leverages PolyPid's PLEX drug-delivery platform to provide localized, prolonged antibiotic release at the surgical site.
|
$17.27M |
$3.62
+0.56%
|
|
PULM
Pulmatrix, Inc.
Pulmatrix's core offering is the iSPERSE dry powder drug delivery platform, a direct product category.
|
$17.17M |
$4.65
-1.06%
|
|
LSTA
Lisata Therapeutics, Inc.
Certepetide functions as a drug-delivery platform to enhance tumor penetration and co-administered therapies.
|
$17.16M |
$1.94
-1.02%
|
|
LPCN
Lipocine Inc.
Lipocine leverages the proprietary Lipral drug delivery platform, a core asset that enables oral delivery of challenging molecules and underpins its product candidates.
|
$17.12M |
$3.20
+1.27%
|
|
EVOK
Evoke Pharma, Inc.
Gimoti relies on a nasal drug-delivery platform/technology, making Drug Delivery Platforms a core investable theme for Evoke's product strategy.
|
$16.63M |
$10.74
+0.66%
|
|
LIPO
Lipella Pharmaceuticals Inc.
Lipella's core metastable liposome drug delivery platform enables targeted, localized mucosal drug formulations.
|
$16.19M |
$0.41
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
Veripure represents a drug-delivery platform for pharmaceutical-grade RBS and PV-10 formulations.
|
$14.90M |
$0.07
|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
FHAB constitutes a proprietary drug delivery platform intended to extend half-life and improve tumor targeting of biologics.
|
$14.40M |
$4.78
+4.95%
|
|
HOTH
Hoth Therapeutics, Inc.
BioLexa platform and HT-001 formulation imply a drug delivery platform approach (localized/topical delivery).
|
$14.39M |
$1.14
+4.61%
|
|
CLSD
Clearside Biomedical, Inc.
Clearside's core offering is a drug delivery platform enabling suprachoroidal (eye) delivery and extended-release formulations.
|
$14.24M |
$0.87
-67.93%
|
|
NXGL
NEXGEL, Inc.
NXGEL's hydrogel platform enables drug delivery and controlled release applications.
|
$13.15M |
$1.61
-1.23%
|
|
MBRX
Moleculin Biotech, Inc.
MBRX utilizes liposomal drug delivery formulations for Annamycin, aligning with Drug Delivery Platforms as a major capability.
|
$12.94M |
$0.37
-14.12%
|
Showing page 2 of 3 (230 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
